Pharvaris FY2025 EPS Estimate Raised by Cantor Fitzgerald

Pharvaris N.V. (NASDAQ:PHVS) – Research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for Pharvaris in a research note issued to investors on Thursday, November 13th. Cantor Fitzgerald analyst S. Seedhouse now expects that the company will post earnings per share of ($2.81) for the year, up from their previous estimate of ($2.87). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. Cantor Fitzgerald also issued estimates for Pharvaris’ FY2026 earnings at ($2.61) EPS.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Thursday, November 13th. JMP Securities decreased their price objective on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 13th. Morgan Stanley lifted their price objective on Pharvaris from $34.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Finally, Wedbush upped their target price on Pharvaris from $27.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.57.

Pharvaris Trading Down 3.8%

Shares of PHVS stock opened at $23.97 on Monday. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -7.47 and a beta of -2.78. The firm has a 50-day moving average price of $23.26 and a 200 day moving average price of $20.78. Pharvaris has a twelve month low of $11.51 and a twelve month high of $26.33.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.08.

Hedge Funds Weigh In On Pharvaris

A number of large investors have recently modified their holdings of PHVS. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new position in shares of Pharvaris in the 2nd quarter valued at about $57,000. JPMorgan Chase & Co. raised its holdings in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Pharvaris during the third quarter valued at approximately $75,000. Public Employees Retirement System of Ohio lifted its position in Pharvaris by 39.3% during the third quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock valued at $156,000 after buying an additional 1,769 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after buying an additional 1,695 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.